chore: daily discovery 2026-04-15
This commit is contained in:
github-actions[bot]
parent
01ea2f1dc4
commit
fb26abb06c
|
|
@ -3,32 +3,47 @@
|
|||
"llm_provider": "google",
|
||||
"recommendations": [
|
||||
{
|
||||
"ticker": "SEE",
|
||||
"ticker": "ACHC",
|
||||
"rank": 1,
|
||||
"company_name": "Sealed Air Corporation",
|
||||
"description": "Sealed Air Corporation provides packaging solutions in the United States, Europe, the Middle East, Africa, and Asia Pacific.",
|
||||
"strategy_match": "volume_divergence",
|
||||
"pipeline": "volume_divergence",
|
||||
"final_score": 75,
|
||||
"company_name": "Acadia Healthcare Company, Inc.",
|
||||
"description": "Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico.",
|
||||
"strategy_match": "short_squeeze",
|
||||
"pipeline": "short_squeeze",
|
||||
"final_score": 85,
|
||||
"confidence": 8,
|
||||
"risk_level": "low",
|
||||
"reason": "The primary edge is a strong OBV divergence signaling multi-week institutional accumulation, corroborated by a highly bullish options P/C ratio of 0.475. Timing is urgent as the stock is exhibiting extreme volatility contraction (Bollinger Bandwidth of 1.3%) while holding above the 50 SMA at $41.82, a classic precursor to an explosive breakout. The risk/reward profile is highly favorable with a tight structural stop-loss available, while a 10.3% short interest provides latent fuel for a potential squeeze. The key risk is the RSI at 69.8, indicating the stock is nearing overbought levels and must break out on strong volume to avoid immediate rejection.",
|
||||
"entry_price": 42.15,
|
||||
"risk_level": "moderate",
|
||||
"reason": "This is a prime short squeeze setup featuring an extreme 42.1% short interest and 6.5 days to cover, a strategy boasting a historical 60.0% 7-day win rate. The stock is exhibiting momentum acceleration, breaking into a strong uptrend well above its 50-day SMA of $21.24 with rising on-balance volume. Options market sentiment strongly corroborates the technical breakout, marked by an unusually low 0.31 put/call volume ratio indicating heavy call accumulation. The primary risk is a broader market selloff or premature profit-taking ahead of their upcoming April 29th earnings report.",
|
||||
"entry_price": 26.610000610351562,
|
||||
"discovery_date": "2026-04-15",
|
||||
"status": "open"
|
||||
},
|
||||
{
|
||||
"ticker": "V",
|
||||
"ticker": "ANAB",
|
||||
"rank": 2,
|
||||
"company_name": "Visa Inc.",
|
||||
"description": "Visa Inc. operates as a payment technology company in the United States and internationally.",
|
||||
"company_name": "AnaptysBio, Inc.",
|
||||
"description": "AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.",
|
||||
"strategy_match": "short_squeeze",
|
||||
"pipeline": "short_squeeze",
|
||||
"final_score": 82,
|
||||
"confidence": 8,
|
||||
"risk_level": "high",
|
||||
"reason": "This setup combines a high squeeze potential (30.6% short interest, 9.8 days to cover) with a hard, impending catalyst: the April 20 spin-off of First Tracks Biotherapeutics. With the corporate action just 5 days away, shorts are heavily incentivized to cover to avoid corporate action liabilities, supported by a fresh MACD bullish crossover with a positive 0.816 histogram. The options flow further corroborates the bullish setup with a low 0.41 put/call volume ratio against a strong technical uptrend. However, the thesis carries risk due to recent insider selling of approximately $2.2M by the CEO and Director, alongside a high ATR of 6.0% demanding careful position sizing.",
|
||||
"entry_price": 67.88999938964844,
|
||||
"discovery_date": "2026-04-15",
|
||||
"status": "open"
|
||||
},
|
||||
{
|
||||
"ticker": "EQR",
|
||||
"rank": 3,
|
||||
"company_name": "Equity Residential",
|
||||
"description": "Equity Residential owns and manages 312 rental properties consisting of 85,190 apartment units primarily in major U.S. coastal and high-growth metro areas.",
|
||||
"strategy_match": "volume_divergence",
|
||||
"pipeline": "volume_divergence",
|
||||
"final_score": 68,
|
||||
"confidence": 6,
|
||||
"risk_level": "moderate",
|
||||
"reason": "The setup offers a compelling accumulation edge, with OBV rising by 32.2% of average volume despite flat price action, backed by highly unusual ITM call buying where the 280 strike traded at 8.92x open interest. The timing is supported by a fresh MACD bullish crossover and price action pushing against the upper Bollinger Band. This creates an attractive risk/reward scenario anchored by elite fundamentals (54.0% ROE, 7.33 Altman Z-Score) as it attempts a trend reversal. The primary risk is technical overhead, as the broader trend remains bearish and failure to decisively reclaim the 50 SMA at $312.96 would invalidate the upside thesis.",
|
||||
"entry_price": 312.67999267578125,
|
||||
"final_score": 75,
|
||||
"confidence": 7,
|
||||
"risk_level": "low",
|
||||
"reason": "The stock presents a robust quantitative volume divergence signal, with OBV running +22.1% above average volume while the price remained flat (+1.8%), indicating covert multi-week institutional accumulation. Technical indicators are aligning favorably right now, characterized by a fresh MACD bullish crossover and the price holding firmly above its 20-day EMA and VWAP. Unusually high volume on deep ITM options, specifically 751 volume on $50 strike calls against an OI of just 2, alongside a low volatility profile (ATR 1.9%) offers an attractive low-risk entry. As a REIT, the primary risk is macroeconomic interest rate sensitivity which could unexpectedly compress valuation multiples despite the technical breakout.",
|
||||
"entry_price": 61.290000915527344,
|
||||
"discovery_date": "2026-04-15",
|
||||
"status": "open"
|
||||
}
|
||||
|
|
|
|||
File diff suppressed because it is too large
Load Diff
|
|
@ -0,0 +1,123 @@
|
|||
{
|
||||
"trade_date": "2026-04-15",
|
||||
"tickers": [
|
||||
"RVMD",
|
||||
"CAR",
|
||||
"ORCL",
|
||||
"HOLX",
|
||||
"EXAS",
|
||||
"PAYC",
|
||||
"CINF",
|
||||
"NI",
|
||||
"CMCSA",
|
||||
"AVB",
|
||||
"CTRA",
|
||||
"EA",
|
||||
"EQR",
|
||||
"DTST",
|
||||
"KOPN",
|
||||
"CCEL",
|
||||
"ANGO",
|
||||
"GIPR",
|
||||
"PXED",
|
||||
"BEEM",
|
||||
"RPM",
|
||||
"ARAI",
|
||||
"NEOG",
|
||||
"FAT",
|
||||
"CARM",
|
||||
"GRDX",
|
||||
"MTB",
|
||||
"OLOX",
|
||||
"BPTH",
|
||||
"HOMB",
|
||||
"TRAW",
|
||||
"CLSD",
|
||||
"LFLY",
|
||||
"INTU",
|
||||
"COIN",
|
||||
"NVDA",
|
||||
"IRDM",
|
||||
"AME",
|
||||
"CTAS",
|
||||
"ETN",
|
||||
"CAMP",
|
||||
"JBL",
|
||||
"DIOD",
|
||||
"SMC",
|
||||
"LW",
|
||||
"SG",
|
||||
"HTO",
|
||||
"RPAY",
|
||||
"BETR",
|
||||
"GF",
|
||||
"MNR",
|
||||
"ACET",
|
||||
"CHPT",
|
||||
"WKSP",
|
||||
"CNXC",
|
||||
"SVBL",
|
||||
"FROPX",
|
||||
"FRBBX",
|
||||
"SWZ",
|
||||
"ABX",
|
||||
"ACHC",
|
||||
"AI",
|
||||
"ARCT",
|
||||
"ANAB",
|
||||
"RIME",
|
||||
"AR"
|
||||
],
|
||||
"filtered_tickers": [
|
||||
"RPM",
|
||||
"ABX",
|
||||
"ACHC",
|
||||
"ANAB",
|
||||
"CTRA",
|
||||
"AME",
|
||||
"CTAS",
|
||||
"ETN",
|
||||
"AR",
|
||||
"EA",
|
||||
"EQR"
|
||||
],
|
||||
"final_ranking": [
|
||||
{
|
||||
"rank": 1,
|
||||
"ticker": "ACHC",
|
||||
"company_name": "Acadia Healthcare Company, Inc.",
|
||||
"current_price": 26.610000610351562,
|
||||
"strategy_match": "short_squeeze",
|
||||
"final_score": 85,
|
||||
"confidence": 8,
|
||||
"risk_level": "moderate",
|
||||
"reason": "This is a prime short squeeze setup featuring an extreme 42.1% short interest and 6.5 days to cover, a strategy boasting a historical 60.0% 7-day win rate. The stock is exhibiting momentum acceleration, breaking into a strong uptrend well above its 50-day SMA of $21.24 with rising on-balance volume. Options market sentiment strongly corroborates the technical breakout, marked by an unusually low 0.31 put/call volume ratio indicating heavy call accumulation. The primary risk is a broader market selloff or premature profit-taking ahead of their upcoming April 29th earnings report.",
|
||||
"description": "Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico."
|
||||
},
|
||||
{
|
||||
"rank": 2,
|
||||
"ticker": "ANAB",
|
||||
"company_name": "AnaptysBio, Inc.",
|
||||
"current_price": 67.88999938964844,
|
||||
"strategy_match": "short_squeeze",
|
||||
"final_score": 82,
|
||||
"confidence": 8,
|
||||
"risk_level": "high",
|
||||
"reason": "This setup combines a high squeeze potential (30.6% short interest, 9.8 days to cover) with a hard, impending catalyst: the April 20 spin-off of First Tracks Biotherapeutics. With the corporate action just 5 days away, shorts are heavily incentivized to cover to avoid corporate action liabilities, supported by a fresh MACD bullish crossover with a positive 0.816 histogram. The options flow further corroborates the bullish setup with a low 0.41 put/call volume ratio against a strong technical uptrend. However, the thesis carries risk due to recent insider selling of approximately $2.2M by the CEO and Director, alongside a high ATR of 6.0% demanding careful position sizing.",
|
||||
"description": "AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States."
|
||||
},
|
||||
{
|
||||
"rank": 3,
|
||||
"ticker": "EQR",
|
||||
"company_name": "Equity Residential",
|
||||
"current_price": 61.290000915527344,
|
||||
"strategy_match": "volume_divergence",
|
||||
"final_score": 75,
|
||||
"confidence": 7,
|
||||
"risk_level": "low",
|
||||
"reason": "The stock presents a robust quantitative volume divergence signal, with OBV running +22.1% above average volume while the price remained flat (+1.8%), indicating covert multi-week institutional accumulation. Technical indicators are aligning favorably right now, characterized by a fresh MACD bullish crossover and the price holding firmly above its 20-day EMA and VWAP. Unusually high volume on deep ITM options, specifically 751 volume on $50 strike calls against an OI of just 2, alongside a low volatility profile (ATR 1.9%) offers an attractive low-risk entry. As a REIT, the primary risk is macroeconomic interest rate sensitivity which could unexpectedly compress valuation multiples despite the technical breakout.",
|
||||
"description": "Equity Residential owns and manages 312 rental properties consisting of 85,190 apartment units primarily in major U.S. coastal and high-growth metro areas."
|
||||
}
|
||||
],
|
||||
"status": "ranked"
|
||||
}
|
||||
|
|
@ -0,0 +1,93 @@
|
|||
# Discovery Analysis - 2026-04-15
|
||||
|
||||
**LLM Provider**: GOOGLE
|
||||
**Models**: Shallow=gemini-2.5-flash-lite, Deep=gemini-3-pro-preview
|
||||
|
||||
## Top Investment Opportunities
|
||||
|
||||
### #1: ACHC
|
||||
|
||||
**Company:** Acadia Healthcare Company, Inc.
|
||||
|
||||
**Current Price:** $26.61
|
||||
|
||||
**Strategy:** short_squeeze
|
||||
|
||||
**Score:** 85 | **Confidence:** 8/10 | **Risk:** Moderate
|
||||
|
||||
**Description:**
|
||||
|
||||
> Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico.
|
||||
|
||||
**Investment Thesis:**
|
||||
|
||||
This is a prime short squeeze setup featuring an extreme 42.1% short interest and 6.5 days to cover, a strategy boasting a historical 60.0% 7-day win rate.
|
||||
|
||||
The stock is exhibiting momentum acceleration, breaking into a strong uptrend well above its 50-day SMA of $21.24 with rising on-balance volume.
|
||||
|
||||
Options market sentiment strongly corroborates the technical breakout, marked by an unusually low 0.31 put/call volume ratio indicating heavy call accumulation.
|
||||
|
||||
The primary risk is a broader market selloff or premature profit-taking ahead of their upcoming April 29th earnings report.
|
||||
|
||||
---
|
||||
|
||||
### #2: ANAB
|
||||
|
||||
**Company:** AnaptysBio, Inc.
|
||||
|
||||
**Current Price:** $67.89
|
||||
|
||||
**Strategy:** short_squeeze
|
||||
|
||||
**Score:** 82 | **Confidence:** 8/10 | **Risk:** High
|
||||
|
||||
**Description:**
|
||||
|
||||
> AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
|
||||
|
||||
**Investment Thesis:**
|
||||
|
||||
This setup combines a high squeeze potential (30.6% short interest, 9.8 days to cover) with a hard, impending catalyst: the April 20 spin-off of First Tracks Biotherapeutics.
|
||||
|
||||
With the corporate action just 5 days away, shorts are heavily incentivized to cover to avoid corporate action liabilities, supported by a fresh MACD bullish crossover with a positive 0.816 histogram.
|
||||
|
||||
The options flow further corroborates the bullish setup with a low 0.41 put/call volume ratio against a strong technical uptrend.
|
||||
|
||||
However, the thesis carries risk due to recent insider selling of approximately $2.2M by the CEO and Director, alongside a high ATR of 6.0% demanding careful position sizing.
|
||||
|
||||
---
|
||||
|
||||
### #3: EQR
|
||||
|
||||
**Company:** Equity Residential
|
||||
|
||||
**Current Price:** $61.29
|
||||
|
||||
**Strategy:** volume_divergence
|
||||
|
||||
**Score:** 75 | **Confidence:** 7/10 | **Risk:** Low
|
||||
|
||||
**Description:**
|
||||
|
||||
> Equity Residential owns and manages 312 rental properties consisting of 85,190 apartment units primarily in major U.S. coastal and high-growth metro areas.
|
||||
|
||||
**Investment Thesis:**
|
||||
|
||||
The stock presents a robust quantitative volume divergence signal, with OBV running +22.1% above average volume while the price remained flat (+1.8%), indicating covert multi-week institutional accumulation.
|
||||
|
||||
Technical indicators are aligning favorably right now, characterized by a fresh MACD bullish crossover and the price holding firmly above its 20-day EMA and VWAP.
|
||||
|
||||
Unusually high volume on deep ITM options, specifically 751 volume on $50 strike calls against an OI of just 2, alongside a low volatility profile (ATR 1.9%) offers an attractive low-risk entry.
|
||||
|
||||
As a REIT, the primary risk is macroeconomic interest rate sensitivity which could unexpectedly compress valuation multiples despite the technical breakout.
|
||||
|
||||
---
|
||||
|
||||
|
||||
## All Candidates Analyzed
|
||||
|
||||
Total candidates analyzed: 3
|
||||
|
||||
- **ACHC** (short_squeeze)
|
||||
- **ANAB** (short_squeeze)
|
||||
- **EQR** (volume_divergence)
|
||||
File diff suppressed because one or more lines are too long
File diff suppressed because one or more lines are too long
Loading…
Reference in New Issue